Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mar 31, 2011

Premium

AVI BioPharma, a developer of RNA-based medicines, has named Peter Linsley as its CSO.

Linsley previously served as CSO of Regulus Therapeutics. Prior to that, he was executive director of cancer biology at Merck Research Laboratories.


Rosetta Genomics said that Kenneth Berlin, the firm's president and CEO, has stepped down from its board.

Berlin, who is replaced by board observer Brian Markison, stepped down in observance of good corporate governance practices pursuant to recommendations recently set forth in updated Israeli corporate law, the Rehovot, Israel-based company said.

His role as president and CEO is not affected.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.